Compare PDFS & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDFS | TXMD |
|---|---|---|
| Founded | 1992 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 22.7M |
| IPO Year | 2000 | 2012 |
| Metric | PDFS | TXMD |
|---|---|---|
| Price | $39.00 | $1.95 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $61.50 | N/A |
| AVG Volume (30 Days) | ★ 555.8K | 14.7K |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 73.68 |
| EPS | ★ 0.22 | 0.02 |
| Revenue | N/A | ★ $1,761,000.00 |
| Revenue This Year | $20.46 | $207.74 |
| Revenue Next Year | $20.66 | $2.15 |
| P/E Ratio | $187.64 | ★ $96.50 |
| Revenue Growth | N/A | ★ 35.25 |
| 52 Week Low | $23.55 | $1.08 |
| 52 Week High | $71.69 | $2.95 |
| Indicator | PDFS | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 31.88 | 34.58 |
| Support Level | $30.71 | $1.91 |
| Resistance Level | $48.78 | $2.15 |
| Average True Range (ATR) | 2.71 | 0.05 |
| MACD | -1.58 | -0.01 |
| Stochastic Oscillator | 3.08 | 4.98 |
PDF Solutions Inc provides products and services designed to empower organizations across the semiconductor and electronics ecosystem to connect, collect, manage, and analyze data about design, equipment, manufacturing, and test to improve the yield and quality of their products and operational efficiency. The Company's products, services, and solutions include proprietary software, physical intellectual property (IP) for integrated circuit (IC) designs, electrical measurement hardware tools, methodologies, and professional services.
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.